{"log_id": 3637497187553645773, "direction": 0, "words_result_num": 27, "words_result": [{"probability": {"variance": 2e-06, "average": 0.998641, "min": 0.995704}, "location": {"width": 141, "top": 238, "height": 30, "left": 176}, "words": "哺乳妇女用药"}, {"probability": {"variance": 2.2e-05, "average": 0.998031, "min": 0.975767}, "location": {"width": 800, "top": 279, "height": 46, "left": 223}, "words": "目前尚不明确阿昔替尼是否经人乳汁排泄。由于大多数药物经乳汁排泄,且哺乳婴"}, {"probability": {"variance": 4.9e-05, "average": 0.997631, "min": 0.958376}, "location": {"width": 845, "top": 337, "height": 44, "left": 179}, "words": "儿存在发生阿昔替尼严重不良反应的可能,因此应考虑药物对母体的重要性,决定是否"}, {"probability": {"variance": 2e-06, "average": 0.998806, "min": 0.995907}, "location": {"width": 210, "top": 404, "height": 32, "left": 176}, "words": "终止哺乳或停用药物"}, {"probability": {"variance": 7e-06, "average": 0.997263, "min": 0.992521}, "location": {"width": 120, "top": 459, "height": 32, "left": 191}, "words": "【儿童用药】"}, {"probability": {"variance": 6e-06, "average": 0.998937, "min": 0.988364}, "location": {"width": 499, "top": 506, "height": 37, "left": 224}, "words": "尚未在儿童患者中研究阿昔替尼的安全性和有效性"}, {"probability": {"variance": 0.000355, "average": 0.994098, "min": 0.895088}, "location": {"width": 802, "top": 554, "height": 45, "left": 225}, "words": "在阿昔替尼BID经口给药1个月或更长时间的未成熟小鼠及犬中观察到骨和牙齿"}, {"probability": {"variance": 0.004947, "average": 0.980623, "min": 0.549186}, "location": {"width": 826, "top": 609, "height": 47, "left": 179}, "words": "的毒性。在≥15mg/kg/剂量(约为推荐起始剂量给予患者所得系统暴露量[AUC的6倍"}, {"probability": {"variance": 0.005013, "average": 0.980986, "min": 0.584578}, "location": {"width": 841, "top": 663, "height": 48, "left": 187}, "words": "5倍),观察到小鼠和犬的包括生长板增厚的骨骼影响。在以>5mg/kg/剂量(约为推荐"}, {"probability": {"variance": 0.000168, "average": 0.994811, "min": 0.924511}, "location": {"width": 810, "top": 719, "height": 43, "left": 181}, "words": "起始剂量给予患者所得AUC的1.5倍)每日两次给药的小鼠中,观察到生长中的"}, {"probability": {"variance": 0.013041, "average": 0.962616, "min": 0.403626}, "location": {"width": 880, "top": 763, "height": 62, "left": 179}, "words": "出现异常(包括龋齿、牙齿咬合不正、破损和或缺失)。尚未在年幼动物中进行有关心"}, {"probability": {"variance": 0.0266, "average": 0.951142, "min": 0.386204}, "location": {"width": 287, "top": 836, "height": 36, "left": 181}, "words": "科患者的其他潜在毒性的评"}, {"probability": {"variance": 0, "average": 0.932246, "min": 0.932246}, "location": {"width": 118, "top": 845, "height": 60, "left": 887}, "words": "不"}, {"probability": {"variance": 1e-06, "average": 0.998775, "min": 0.99721}, "location": {"width": 130, "top": 894, "height": 34, "left": 186}, "words": "【老年用药】"}, {"probability": {"variance": 0.002615, "average": 0.987419, "min": 0.679192}, "location": {"width": 800, "top": 936, "height": 44, "left": 228}, "words": "在接受阿昔替尼治疗的RCC患者对照临床研究中,接受阿昔替尼治疗的123/359"}, {"probability": {"variance": 6e-06, "average": 0.997717, "min": 0.993616}, "location": {"width": 91, "top": 1006, "height": 26, "left": 184}, "words": "例患者("}, {"probability": {"variance": 0.000827, "average": 0.992271, "min": 0.830596}, "location": {"width": 695, "top": 991, "height": 43, "left": 334}, "words": "≥65岁。尽管不能排除某些年长患者的敏感性较高,但在≥65岁与65岁"}, {"probability": {"variance": 1e-05, "average": 0.99806, "min": 0.987068}, "location": {"width": 655, "top": 1048, "height": 43, "left": 185}, "words": "以下患者间,总体上未观察到阿昔替尼的安全性和有效性存在差异"}, {"probability": {"variance": 2.3e-05, "average": 0.997415, "min": 0.975772}, "location": {"width": 589, "top": 1104, "height": 39, "left": 229}, "words": "老年患者无需调整剂量(见【用法用量】和【药代动力学】)"}, {"probability": {"variance": 0.00024, "average": 0.990786, "min": 0.951609}, "location": {"width": 169, "top": 1168, "height": 30, "left": 192}, "words": "【药物相互作用】"}, {"probability": {"variance": 0.001542, "average": 0.98345, "min": 0.792966}, "location": {"width": 801, "top": 1209, "height": 45, "left": 231}, "words": "体外数据显示阿昔替尼主要经CYP3A4/5代谢,少量经 CYPIA2、CYP2C19和尿"}, {"probability": {"variance": 0.0103, "average": 0.967824, "min": 0.565042}, "location": {"width": 484, "top": 1271, "height": 41, "left": 187}, "words": "苷二磷酸葡萄糖醛酸基转移酶(UGT)1A1代谢"}, {"probability": {"variance": 0.000419, "average": 0.976904, "min": 0.931468}, "location": {"width": 173, "top": 1335, "height": 33, "left": 187}, "words": "CYP3A4/5抑制剂"}, {"probability": {"variance": 0.000251, "average": 0.992932, "min": 0.913402}, "location": {"width": 801, "top": 1374, "height": 46, "left": 232}, "words": "酮康唑是CYP3A4/5的强效抑制剂,在健康志愿者中以400mg每日一次的剂量给"}, {"probability": {"variance": 0.000122, "average": 0.994387, "min": 0.955971}, "location": {"width": 840, "top": 1429, "height": 49, "left": 189}, "words": "药7天,可使单次口服5mg阿昔替尼的平均曲线下面积(AUC)升高2倍,使Cm"}, {"probability": {"variance": 0.000141, "average": 0.99175, "min": 0.960456}, "location": {"width": 136, "top": 1584, "height": 28, "left": 549}, "words": "第14页,共27页"}, {"probability": {"variance": 0.000332, "average": 0.980353, "min": 0.962127}, "location": {"width": 17, "top": 1619, "height": 18, "left": 279}, "words": "20"}], "language": 3}